Evidence map›Paper›PMID 42556344›Full record

ArticleCell reports. Medicine2026

Corpora amylacea profiling reveals disease stage and brain region-specific alterations in glycogen metabolism in Alzheimer's disease patient brains.

Jonathan A B Villareal, Tim Bathe, Ana de la Rosa, Rohan V Sharma, Elvin O Hernández Gómez, Alison M Ryan, Tara R Hawkinson, Anthony M Tuzzolo, Eduardo Medina-Parrilla, Jennifer L Phillips and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jonathan A B VillarealDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.
Tim BatheDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany; Graduate School of Systemic Neurosciences (GSN), Department Biology II Neurobiology, LMU Munich, 82152 Planegg-Martinsried, Germany.
Ana de la RosaDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.
Rohan V SharmaCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.
Elvin O Hernández GómezCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.
Alison M RyanCenter for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA.
Tara R HawkinsonCenter for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA.
Anthony M TuzzoloDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.
Eduardo Medina-ParrillaDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.
Jennifer L PhillipsDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.
Wangchen TseringDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Andrea A IturbeCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA.
Benoit I GiassonCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Ramon C SunCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA; Center for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA.
Matthew S GentryMcKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA; Center for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA.
Stefan ProkopDepartment of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA; Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA; McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: sprokop@ufl.edu.

Funding

Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Ranjan Duara, DAVID LOEWENSTEIN · 2020 to 2026
$25.6M
Brain Glucose Deficiency: Mechanisms and ModulationRM1NS133593 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Joseph J. Pancrazio, Juan M. Pascual · 2023 to 2026
$5.3M
Deciphering the Glycan Code in Human Alzheimer’s Disease BrainR01AG078702 · NIA · UNIVERSITY OF KENTUCKY · PI Peggi M Angel, Sean Curtis Bendall · 2022 to 2026
$3.8M
Aberrant Glycogen in Lung Adenocarcinoma TumorigenesisR01CA266004 · NCI · UNIVERSITY OF KENTUCKY · PI Matthew S. Gentry, Ramon C. Sun · 2022 to 2026
$2.6M
Aberrant Glycogen Modulates Cerebral Glucose Metabolism in Aging and Alzheimer's DiseaseR01AG066653 · NIA · UNIVERSITY OF KENTUCKY · PI SUN, RAMON C. · 2020 to 2024
$1.9M
Targeting Glycogen Metabolism in Ewing's Sarcoma: Diagnostic, Prognostic, and Therapeutic ApplicationsR01CA288696 · NCI · UNIVERSITY OF FLORIDA · PI Matthew S. Gentry, Ramon C. Sun · 2024 to 2026
$1.8M
Medical Scientist Training Program at the University of FloridaT32GM163993 · NIGMS · UNIVERSITY OF FLORIDA · PI JENNIFER Lynn BIZON, MARK S. SEGAL · 2026 to 2026
$236k
NCI NIH HHS R01 CA266004NCI NIH HHS R01 CA288696NIA NIH HHS P30 AG066506NIA NIH HHS R01 AG066653NIA NIH HHS R01 AG078702NIGMS NIH HHS T32 GM163993NINDS NIH HHS RM1 NS133593
6 · The paper itself

Abstract

Increasing evidence indicates that shifts in brain polysaccharide metabolism can influence the progression of multiple neurodegenerative diseases. Here, we profile corpora amylacea (CA) in 230 postmortem human brains, revealing significantly higher densities in Alzheimer's disease (AD) patients when compared with patients with other or no neurodegenerative diseases and a tight correlation of CA density with neurofibrillary tangle (NFT) pathology. Immunohistochemical profiling using an anti-glycogen antibody confirms the polysaccharide nature of CA and reveals plaque-like glycogen patches (GPs) and densely aggregated intraneuronal glycogen in AD patient brains correlated with the emergence of NFT pathology. matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) orthogonally verifies the polysaccharide identity of these structures and that GPs can be consistently observed at early neuropathological disease stages. GPs are also observed in murine models of AD-like pathology, correlating with tau pathology. The identification of these AD-associated glycogen pathologies in the human brain implies that alterations in glycogen metabolism are tightly associated with AD pathogenesis.

Indexed as

Alzheimer DiseaseBrainGlycogenAgedAged, 80 and overAnimalsFemaleHumansMaleMiceNeurofibrillary TanglesPolysaccharidestau ProteinsGlycogenPolysaccharidestau ProteinsAlzheimer’s diseaseamyloid-βcorpora amylaceaglycogenmetabolismtau

Identifiers

PMID42556344
PMCPMC13522764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.